Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities

Marta Zarandi, Jozsef L. Varga, Andrew V. Schally, J. Horváth, Gabor L. Toller, Magdolna Kovacs, Markus Letsch, Kate Groot, Patricia Armatis, Gabor Halmos

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Antagonists of growth hormone-releasing hormone (GHRH) synthesized previously inhibit proliferation of various human cancers, but derivatisation with fatty acids could enhance their clinical efficacy. We synthesized a series of antagonists of GHRH(1-29)NH2 acylated at the N terminus with monocarboxylic or α,ω-dicarboxylic acids containing six to sixteen carbon atoms. These peptides are analogs of prior potent antagonists JV-1-36, JV-1-38, and JV-1-65 with phenylacetyl group at their N terminus. Several new analogs, including MZ-J-7-46 and MZ-J-7-30, more effectively inhibited GHRH-induced GH release in vitro in a su perfused rat pituitary system than their parent compound JV-1-36 and had increased binding affinities to rat pituitary GHRH receptors, but they showed weaker inhibition of GH release in vivo than JV-1-36. All antagonists acylated with fatty acids containing 8-14 carbon atoms inhibited the proliferation of MiaPaCa-2 human pancreatic cancer cells in vitro better than JV-1-36 or JV-1-65. GHRH antagonist MZ-J-7-114 (5 μg/day) significantly suppressed the growth of PC-3 human androgen-independent prostate cancers xenografted into nude mice and reduced serum IGF-I levels, whereas antagonist JV-1-38 had no effect at the dose of 10 μg/day. GHRH antagonists including MZ-J-7-46 and MZ-J-7-114 acylated with octanoic acid and MZ-J-7-30 and MZ-J-7-110 acylated with 1,12-dodecanedicarboxylic acid represent relevant improvements over earlier antagonists. These and previous results suggest that this class of GHRH antagonists might be effective in the treatment of various cancers.

Original languageEnglish
Pages (from-to)4610-4615
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number12
DOIs
Publication statusPublished - Mar 21 2006

Fingerprint

Lipopeptides
Growth Hormone-Releasing Hormone
Hormone Antagonists
Pituitary Hormone-Regulating Hormone Receptors
Fatty Acids
Carbon
Dicarboxylic Acids
Pancreatic Neoplasms
Insulin-Like Growth Factor I
Nude Mice
Androgens
Growth Hormone
Neoplasms
Prostatic Neoplasms
Peptides
Acids
JV 1-36
Growth
Serum

Keywords

  • Antagonistic analogs
  • Cancer therapy
  • Proliferation

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. / Zarandi, Marta; Varga, Jozsef L.; Schally, Andrew V.; Horváth, J.; Toller, Gabor L.; Kovacs, Magdolna; Letsch, Markus; Groot, Kate; Armatis, Patricia; Halmos, Gabor.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 12, 21.03.2006, p. 4610-4615.

Research output: Contribution to journalArticle

Zarandi, Marta ; Varga, Jozsef L. ; Schally, Andrew V. ; Horváth, J. ; Toller, Gabor L. ; Kovacs, Magdolna ; Letsch, Markus ; Groot, Kate ; Armatis, Patricia ; Halmos, Gabor. / Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 12. pp. 4610-4615.
@article{3cc360d8181e47a890a234990555fbc2,
title = "Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities",
abstract = "Antagonists of growth hormone-releasing hormone (GHRH) synthesized previously inhibit proliferation of various human cancers, but derivatisation with fatty acids could enhance their clinical efficacy. We synthesized a series of antagonists of GHRH(1-29)NH2 acylated at the N terminus with monocarboxylic or α,ω-dicarboxylic acids containing six to sixteen carbon atoms. These peptides are analogs of prior potent antagonists JV-1-36, JV-1-38, and JV-1-65 with phenylacetyl group at their N terminus. Several new analogs, including MZ-J-7-46 and MZ-J-7-30, more effectively inhibited GHRH-induced GH release in vitro in a su perfused rat pituitary system than their parent compound JV-1-36 and had increased binding affinities to rat pituitary GHRH receptors, but they showed weaker inhibition of GH release in vivo than JV-1-36. All antagonists acylated with fatty acids containing 8-14 carbon atoms inhibited the proliferation of MiaPaCa-2 human pancreatic cancer cells in vitro better than JV-1-36 or JV-1-65. GHRH antagonist MZ-J-7-114 (5 μg/day) significantly suppressed the growth of PC-3 human androgen-independent prostate cancers xenografted into nude mice and reduced serum IGF-I levels, whereas antagonist JV-1-38 had no effect at the dose of 10 μg/day. GHRH antagonists including MZ-J-7-46 and MZ-J-7-114 acylated with octanoic acid and MZ-J-7-30 and MZ-J-7-110 acylated with 1,12-dodecanedicarboxylic acid represent relevant improvements over earlier antagonists. These and previous results suggest that this class of GHRH antagonists might be effective in the treatment of various cancers.",
keywords = "Antagonistic analogs, Cancer therapy, Proliferation",
author = "Marta Zarandi and Varga, {Jozsef L.} and Schally, {Andrew V.} and J. Horv{\'a}th and Toller, {Gabor L.} and Magdolna Kovacs and Markus Letsch and Kate Groot and Patricia Armatis and Gabor Halmos",
year = "2006",
month = "3",
day = "21",
doi = "10.1073/pnas.0511348103",
language = "English",
volume = "103",
pages = "4610--4615",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "12",

}

TY - JOUR

T1 - Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities

AU - Zarandi, Marta

AU - Varga, Jozsef L.

AU - Schally, Andrew V.

AU - Horváth, J.

AU - Toller, Gabor L.

AU - Kovacs, Magdolna

AU - Letsch, Markus

AU - Groot, Kate

AU - Armatis, Patricia

AU - Halmos, Gabor

PY - 2006/3/21

Y1 - 2006/3/21

N2 - Antagonists of growth hormone-releasing hormone (GHRH) synthesized previously inhibit proliferation of various human cancers, but derivatisation with fatty acids could enhance their clinical efficacy. We synthesized a series of antagonists of GHRH(1-29)NH2 acylated at the N terminus with monocarboxylic or α,ω-dicarboxylic acids containing six to sixteen carbon atoms. These peptides are analogs of prior potent antagonists JV-1-36, JV-1-38, and JV-1-65 with phenylacetyl group at their N terminus. Several new analogs, including MZ-J-7-46 and MZ-J-7-30, more effectively inhibited GHRH-induced GH release in vitro in a su perfused rat pituitary system than their parent compound JV-1-36 and had increased binding affinities to rat pituitary GHRH receptors, but they showed weaker inhibition of GH release in vivo than JV-1-36. All antagonists acylated with fatty acids containing 8-14 carbon atoms inhibited the proliferation of MiaPaCa-2 human pancreatic cancer cells in vitro better than JV-1-36 or JV-1-65. GHRH antagonist MZ-J-7-114 (5 μg/day) significantly suppressed the growth of PC-3 human androgen-independent prostate cancers xenografted into nude mice and reduced serum IGF-I levels, whereas antagonist JV-1-38 had no effect at the dose of 10 μg/day. GHRH antagonists including MZ-J-7-46 and MZ-J-7-114 acylated with octanoic acid and MZ-J-7-30 and MZ-J-7-110 acylated with 1,12-dodecanedicarboxylic acid represent relevant improvements over earlier antagonists. These and previous results suggest that this class of GHRH antagonists might be effective in the treatment of various cancers.

AB - Antagonists of growth hormone-releasing hormone (GHRH) synthesized previously inhibit proliferation of various human cancers, but derivatisation with fatty acids could enhance their clinical efficacy. We synthesized a series of antagonists of GHRH(1-29)NH2 acylated at the N terminus with monocarboxylic or α,ω-dicarboxylic acids containing six to sixteen carbon atoms. These peptides are analogs of prior potent antagonists JV-1-36, JV-1-38, and JV-1-65 with phenylacetyl group at their N terminus. Several new analogs, including MZ-J-7-46 and MZ-J-7-30, more effectively inhibited GHRH-induced GH release in vitro in a su perfused rat pituitary system than their parent compound JV-1-36 and had increased binding affinities to rat pituitary GHRH receptors, but they showed weaker inhibition of GH release in vivo than JV-1-36. All antagonists acylated with fatty acids containing 8-14 carbon atoms inhibited the proliferation of MiaPaCa-2 human pancreatic cancer cells in vitro better than JV-1-36 or JV-1-65. GHRH antagonist MZ-J-7-114 (5 μg/day) significantly suppressed the growth of PC-3 human androgen-independent prostate cancers xenografted into nude mice and reduced serum IGF-I levels, whereas antagonist JV-1-38 had no effect at the dose of 10 μg/day. GHRH antagonists including MZ-J-7-46 and MZ-J-7-114 acylated with octanoic acid and MZ-J-7-30 and MZ-J-7-110 acylated with 1,12-dodecanedicarboxylic acid represent relevant improvements over earlier antagonists. These and previous results suggest that this class of GHRH antagonists might be effective in the treatment of various cancers.

KW - Antagonistic analogs

KW - Cancer therapy

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=33645230203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645230203&partnerID=8YFLogxK

U2 - 10.1073/pnas.0511348103

DO - 10.1073/pnas.0511348103

M3 - Article

C2 - 16537407

AN - SCOPUS:33645230203

VL - 103

SP - 4610

EP - 4615

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 12

ER -